Compare Deere & Company (DE) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Mesoblast Limited — how do they compare? Deere & Company trades at $618.3 (market cap $164.47B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Deere & Company is far larger — about 76.1× Mesoblast Limited's market cap, and Deere & Company pays a 1.06% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DE | MESO | |
|---|---|---|
Market Cap | $164.47B | $2.16B |
Sector | Industrials | Technology |
52-Week High | $662.49 | $20.96 |
52-Week Low | $439.11 | $12.88 |
Enterprise Value | $219.29B | $2.17B |
Dividend Yield | 1.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $620.83, up 0.97% for the day, with a bullish technical outlook supported by moving averages and recent earnings beats. Revenue declined to $44.67B in 2025, but net income margins remain healthy at 10.33%. The stock is near its pivot point of $620, with support at $613 and resistance at $628. Analyst consensus is a Moderate Buy with a $676.08 price target, reflecting optimism despite cyclical headwinds in agricultural equipment demand.
The outlook is cautiously positive, driven by consistent earnings outperformance and strong institutional holdings, but investors face risks from revenue volatility and high debt levels. The stock offers value if agricultural recovery materializes, but macroeconomic sensitivity warrants monitoring.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
